Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
BCG018
- Development stage
- Preclinical
- Lead developer
- Biocytogen
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
BCG018 is an antibody-drug conjugate (ADC) targeting integrin αvβ6 (ITGB6), a heterodimeric protein overexpressed in various solid tumors and associated with poor prognosis. Developed by Biocytogen using the RenLite® platform, BCG018 consists of a fully human monoclonal antibody (anti-ITGB6-B) conjugated to BLD1102, a novel topoisomerase I inhibitor payload. The antibody component selectively binds to ITGB6 and its heterodimer αvβ6 with high affinity and is effectively internalized into tumor cells without disrupting the interaction between ITGB6 and its natural ligand, LAP. In preclinical studies, BCG018 demonstrated superior anti-tumor efficacy compared to benchmark ADCs in patient-derived xenograft (PDX) and cell-derived xenograft (CDX) models of pancreatic cancer, colorectal cancer, and non-small cell lung cancer (NSCLC), regardless of ITGB6 expression levels.
- Other names
- anti-ITGB6-B-BLD1102anti-ITGB-6-B-BLD1102anti-ITGB 6-B-BLD1102
02
Targets
TOP1 (DNA Topoisomerase I)αVβ6 (Integrin αVβ6)
Beyond the preview
Go deeper on BCG018.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on BCG018.